Combination of Paraplatin and Alimta Yields Success with Elderly Mesothelioma Patients
Italian researchers report that the combination of Alimta® and Paraplatin® has proven to be an effective palliative therapy for elderly patients with mesothelioma. The findings of this study appeared in an early release, online at the British Journal of Cancer on June 10, 2008.
Mesothelioma, a rare and lethal form of cancer, is caused by asbestos exposure. Approximately 2,500 new, reported cases per year arise in the United States. It is an aggressive disease; those affected survive less than a year from the date of diagnosis.
During the 12th World Conference on Lung Cancer in September, 2007, a study was presented in which the combination of Alimta and Paraplatin was found to have an overall response rate of 22%, a disease control rate of 76%, a one-year survival rate of 64%, and a median time to disease progression of 7 months.
If you or a loved one have recently been diagnosed with mesothelioma, and are concerned about your legal rights, medical bills or the future welfare of your family, please fill out form on this page for a free legal review of your potential case.
Other helpful links:
Asbestos and lung cancer Asbestos and lung cancer
Mesothelioma attorney Mesothelioma attorney
Mesothelioma Lawyer Mesothelioma lawyer
Asbestos attorney Asbestos attorney